NKTX
Nkarta, Inc.
Set alert
- YTD
- -15.68%
- 1 year
- -25.00%
- Open
- 1.66
- Prev close
- 1.66
- Mkt cap
- 111.73M
- Vol
- 1.21M
- Avg vol
- 732.10K
- EPS
- -1.58
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.54
- High
- 1.66
- Forward P/E
- -1.42
- Beta
- 0.87
- Short ratio
- 5.44
- Inst. own
- 99.79%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 13, 2024
- 50-d avg
- 3.03
- 200-d avg
- 5.86
- 1y target
- 15.83
Key statistics
- Market cap
- 176.42M
- Enterprise value
- -30.36M
- Trailing P/E
- 0.00
- Forward P/E
- -1.42
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.41
- EPS (TTM)
- -1.83
- Beta
- 0.87
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -69.58M
- Total cash
- 283.06M
- Total debt
- 85.45M
- Return on equity
- -30.40%
- Shares outstanding
- 70.57M
- Short % of float
- 12.49%
- 50-day average
- 3.03
- 200-day average
- 5.86
Analyst view
Consensus: none
- Target (low)
- 11.00
- Target (mean)
- 15.83
- Target (high)
- 20.00
- Strong buy2
- Buy6
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 13, 2024
Expected Aug 13, 2024. Consensus EPS estimate -0.40.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -0.37 | -0.39 | -0.02 | -5.41% |
| Aug 13, 2024 | Jun 1, 2024 | -0.49 | -0.34 | +0.15 | +30.61% |
| Aug 13, 2024 | Jun 1, 2024 | -0.49 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | -0.56 | -0.58 | -0.02 | -3.57% |
| May 9, 2024 | Mar 1, 2024 | -0.56 | — | — | — |
| Mar 21, 2024 | Dec 1, 2023 | -0.62 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 21, 2024 | Mizuho | main | Outperform | Outperform |
| Nov 11, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Nov 8, 2024 | Needham | main | Buy | Buy |
| Aug 15, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Aug 14, 2024 | Needham | reit | Buy | Buy |
| Aug 14, 2024 | Raymond James | up | Outperform | Strong Buy |
About Nkarta, Inc.
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- nkartatx.com
News
- Nkarta Targets ACR 2026 Data Reveal as Outpatient CAR NK Trials Advance
- Nkarta Targets ACR 2026 Data Reveal as Outpatient CAR NK Trials Advance
- Nkarta (NASDAQ:NKTX) Stock Falls 3.5% – Here’s Why
- Nkarta to Participate in September Investor Conferences
- Nkarta to Present Initial Autoimmune Clinical Data for NKX019 at American College of Rheumatology (ACR) Convergence 2026
- 6,300,212 Shares in Nkarta, Inc. $NKTX Acquired by BlackRock Inc.
- Stifel Maintains Buy on Nkarta, Lowers Price Target to $10
- HC Wainwright & Co. Maintains Buy on Nkarta, Lowers Price Target to $14
- Nkarta Q2 EPS $(0.54) Misses $(0.38) Estimate
- Cyllene Therapeutics Expands Leadership Team to Support Corporate Growth and Clinical Product Development
Your note
Sign in to keep a note on NKTX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BRANDENBERGER RALPH ERIK | Chief Technology Officer | Sale | Jun 17, 2024 | 79,743 |
| GEORGE SIMEON J. | Director | Purchase | Mar 26, 2024 | 0 |
| HAGER ALICIA J | Officer | Sale | Jul 15, 2024 | 103,819 |
| HASTINGS PAUL J | Chief Executive Officer | Sale | Jun 17, 2024 | 240,737 |
| LEVIN ALYSSA | Chief Financial Officer | Stock Award(Grant) | Jan 3, 2024 | 56,000 |
| MAHMOOD NADIR AHMEDUDDIN | Chief Financial Officer | Sale | Jun 19, 2023 | 85,776 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| RA Capital Management, L.P. | 15.31% | 10,805,129 | 27.01M | Sep 29, 2024 |
| Commodore Capital Lp | 6.61% | 4,662,073 | 11.66M | Sep 29, 2024 |
| Blackrock Inc. | 5.98% | 4,222,380 | 10.56M | Sep 29, 2024 |
| Boxer Capital, LLC | 5.71% | 4,029,606 | 10.07M | Sep 29, 2024 |
| Samsara BioCapital, LLC | 5.34% | 3,768,035 | 9.42M | Sep 29, 2024 |
| Adage Capital Partners GP L.L.C. | 5.10% | 3,600,000 | 9.00M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.58% | 1,818,558 | 4.55M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 1.95% | 1,373,111 | 3.43M | Oct 30, 2024 |
| Wasatch Ultra Growth Fund | 1.45% | 1,024,570 | 2.56M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.00% | 704,875 | 1.76M | Sep 29, 2024 |
| Wasatch Microcap Fund | 0.95% | 668,362 | 1.67M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 0.77% | 542,221 | 1.36M | Aug 30, 2024 |